Product Program year 2025 Source: CMS Open Payments

Fyarro

Drug Cancer

NDC 80803-153-50

Open in the dashboard

General payments

$733,945

2,299 payments

Research payments

$0

0 payments

Through program year 2025, $733,945 in general payments and $0 in research payments were reported against Fyarro (Cancer).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2025 General $324,850 1,392
2024 General $53,623 370
2023 General $355,472 537

Breakdown

Who paid General payments · program years 2023–2025
  1. Aadi Bioscience, Inc. $547,457 1,116 payments
  2. Fennec Pharmaceuticals, Inc. $186,488 1,183 payments
Top recipients General payments · program year 2025
  1. Ralph Boccia Hematology & Oncology · Bethesda, MD $50,115 15% · 15 payments
  2. Susan Jerian Internal Medicine · Westlake Village, CA $44,450 14% · 4 payments
  3. Leslie Worona Nurse Practitioner, Family · New York, NY $42,432 13% · 24 payments
  4. Veronica Vestal Hematology & Oncology · Toa Baja, PR $33,112 10% · 10 payments
  5. Scott Penney Pediatric Hematology-Oncology · San Antonio, TX $21,927 7% · 16 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $139,493 43% · 350 practitioners
  2. Internal Medicine $50,599 16% · 24 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $46,695 14% · 122 practitioners
  4. Medical Oncology Internal Medicine $29,395 9% · 139 practitioners
  5. Pediatric Hematology-Oncology Pediatrics $22,641 7% · 8 practitioners

The top 5 of 42 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $63,996 20% · 169 recipients
  2. Maryland $55,277 17% · 22 recipients
  3. New York $54,438 17% · 13 recipients
  4. Puerto Rico $33,736 10% · 7 recipients
  5. Texas $29,959 9% · 63 recipients

The top 5 of 42 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

2,299 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record